Systematic Review: No Effective Drugs for Prolonged Grief Disorder

Current Pharmacological Treatments Show No Efficacy for Prolonged Grief Disorder

A systematic review published on November 2, 2026, concludes that no existing pharmacological treatments are effective for prolonged grief disorder (PGD), a diagnosis recently added to both the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) and the International Classification of Diseases, 11th Revision (ICD-11). The review, accessible via OpenAlex, synthesized data from 33 studies—including 16 clinical trials—covering over 211,000 participants. Despite the breadth of research, no medication class, including commonly prescribed antidepressants, demonstrated significant benefit over placebo or control in reducing core grief symptoms. The standardized mean difference (SMD) for pharmacological interventions on grief was negligible (−0.06; 95% CI, –0.31–0.19), and the effect on depression in bereaved individuals was small and not statistically significant (–0.29; 95% CI, –0.68–0.10).

Mechanisms and Context: Why Current Medications Fall Short

Prolonged grief disorder is characterized by persistent, pervasive grief that extends beyond culturally expected periods, often impairing daily function. The pathophysiology of PGD diverges from major depressive disorder (MDD), despite overlapping symptoms, which may explain why traditional antidepressants and other psychiatric medications have failed to show efficacy. The review found that while some interventions, such as selective serotonin reuptake inhibitors (SSRIs) and beta blockers, may alleviate secondary depressive symptoms, they do not address the core features of grief itself. Notably, the review highlights that most studies were not designed specifically for PGD as a distinct diagnosis, reflecting the relatively recent formalization of this disorder in diagnostic manuals. This diagnostic lag may have contributed to the lack of targeted, high-quality pharmacological research.

Policy and Research Implications: A Case for Novel Interventions

The absence of effective pharmacological options for PGD represents a significant unmet need in mental health care. The review's findings may serve as a catalyst for both public and private research funders to prioritize the development and testing of novel interventions. One emerging area of interest is psychedelic-assisted therapy, which has shown early promise for other treatment-resistant conditions such as depression and post-traumatic stress disorder (PTSD). With no current medications meeting the needs of PGD patients, regulatory agencies and institutional review boards may be more inclined to approve and expedite well-designed clinical trials investigating psychedelics—such as psilocybin or MDMA—as adjuncts to psychotherapy for grief-related distress. This shift could also influence insurance coverage and reimbursement policies, as payers seek evidence-based solutions for a disorder now recognized in major diagnostic systems.

• Insight: The review notes that inconsistent diagnostic criteria and outcome measures across studies have hampered progress, suggesting that future trials must adopt standardized definitions and validated assessment tools for PGD to generate actionable data.

Risks, Unknowns, and Methodological Challenges

Despite the urgency for new treatments, the review underscores significant risks and unknowns. The quality of existing studies was generally low, with frequent methodological weaknesses such as small sample sizes, lack of blinding, and inconsistent reporting of outcomes. This raises concerns about the reliability of both negative and positive findings in the literature. For psychedelic-assisted therapies specifically, there is currently no published phase 2 or phase 3 data for PGD, and the safety profile in bereaved populations—who may be uniquely vulnerable—remains uncharacterized. Furthermore, the review cautions that pharmacological approaches alone may be insufficient, given the complex social, cultural, and existential dimensions of grief. Any future interventions, psychedelic or otherwise, must be rigorously evaluated for both efficacy and safety, with careful attention to ethical considerations and informed consent.

Looking Ahead: The Path to Rigorous, Targeted Clinical Trials

The findings of this systematic review set the stage for a new era of research into bereavement-related mental health. Stakeholders—including researchers, clinicians, regulators, and industry sponsors—are now tasked with designing and funding high-quality, adequately powered randomized controlled trials (RCTs) that use precise diagnostic criteria and standardized outcome measures for PGD. As psychedelic-assisted therapies move from early-phase trials in other indications toward possible investigation in grief disorders, the field must avoid the pitfalls of past research by prioritizing methodological rigor and patient safety. For now, the absence of effective medications for PGD is a clarion call for innovation, collaboration, and transparency in the development of new therapeutic approaches.

By Dr. Jamie L. Chen, PhD (Neuroscience, University of Toronto). Reviewed by Dr. Priya S. Malik, MD, FRCPC, on 2026-11-03. Research based on primary sources, including the OpenAlex systematic review and DSM-5-TR/ICD-11 diagnostic criteria.